Advanced Search
LIU Yuying, LI Yao, YANG Qiang, CHEN Ran, LI Kailing, ZHANG Jingqing. Stability and pharmacokinetics of hyaluronic acid-modified asparaginase self-assembled biomimetic nanocapsules[J]. Journal of China Pharmaceutical University, 2020, 51(4): 461-465. DOI: 10.11665/j.issn.1000-5048.20200411
Citation: LIU Yuying, LI Yao, YANG Qiang, CHEN Ran, LI Kailing, ZHANG Jingqing. Stability and pharmacokinetics of hyaluronic acid-modified asparaginase self-assembled biomimetic nanocapsules[J]. Journal of China Pharmaceutical University, 2020, 51(4): 461-465. DOI: 10.11665/j.issn.1000-5048.20200411
shu

Stability and pharmacokinetics of hyaluronic acid-modified asparaginase self-assembled biomimetic nanocapsules

  • 1.

    Chongqing Research Center for Pharmaceutical Engineering, Chongqing Medical University, Chongqing 400016

  • 2.

    Chongqing Public Health Medical Center, Chongqing 400036, China

Funds: This study was supported by the National Natural Science Foundation of China (No.30973645), the Project Foundation of Chongqing Science and Technology Commission (No.CSTC2015jcyjBX0027) and the Project Foundation of Chongqing Municipal Education Committee (No.CYS19210)
More Information
  • Received Date: March 13, 2020
    Graphical Abstract
    • Abstract
  • The stability and pharmacokinetic properties of hyaluronic acid-modified asparaginase (Asp) self-assembled bionic nanocapsules (ASNCs) were preliminarily investigated. ASNCs were prepared by molecular self-assembly method to investigate their morphology, particle size, Zeta potential and antitrypsin stability. After intravenous injection of free Asp and ASNCs, rat plasma samples at different times were taken to determine Asp activity. Pharmacokinetic parameters were calculated by DAS pharmacokinetic software. The particle size of ASNCs was (99.17 ± 0.21) nm and the potential was -(13.13 ± 0.60) mV. In trypsin solution, ASNCs showed more excellent stability. The area under the activity-time curve (AUC0-48 h) of ASNCs was about 2 times higher than that of Asp; the mean residence time (MRT0-48 h) was about 1.7 times higher than that of Asp, and the bioavailability was 195% of Asp. The results showed that ASNCs could improve the stability and bioavailability of Asp against trypsin and prolong the circulation time of Asp in vivo.
    • FullText(HTML)
    • References (15)
  • [1]
    Zhou XY, Liu JJ. Chemical modification of Escherichia coli L-asparaginase with polyethylene glycol[J]. J China Pharm Univ(中国药科大学学报), 2000, 31(3): 230-233.
    [2]
    Huang YJ, Yang L, Li Y, et al. Pharmacokinetic study on asparaginase-evodiamine loaded core-shell lipidic nanoparticles[J]. Chin Pharmacol Bull(中国药理学通报),2019，35(9):1284-1289.
    [3]
    Shi PJ, Fang JP. Study of asparaginase in the treatment of acute lymphoblastic leukemia[J]. Chin J Pract Pediatr(中国实用儿科杂志), 2016, 31(4): 268-274.
    [4]
    Einsfeldt K, Baptista IC, Pereira JC, et al. Recombinant L-asparaginase from Zymomonas mobilis: a potential new antileukemic agent produced in Escherichia coli[J]. PLoS One, 2016, 11(6): e0156692.
    [5]
    Borek D, Kozak M, Pei JM, et al. Crystal structure of active site mutant of antileukemic L-asparaginase reveals conserved zinc-binding site[J]. FEBS J, 2014, 281(18): 4097-4111.
    [6]
    Karamitros CS, Yashchenok AM, M?hwald H, et al. Preserving catalytic activity and enhancing biochemical stability of the therapeutic enzyme asparaginase by biocompatible multilayered polyelectrolyte microcapsules[J]. Biomacromolecules, 2013, 14(12): 4398-4406.
    [7]
    Tian MD, Zhu CM, Luo C, et al. Cytotoxicity of superparamagnetic iron oxide nanoparticles modified by chitosan or sodium oleate[J]. Acad J Second Mil Med Univ(第二军医大学学报), 2014, 35(4): 366-371.
    [8]
    Ashrafi H, Amini M, Mohammadi-Samani S, et al. Nanostructure L-asparaginase-fatty acid bioconjugate: synthesis, preformulation study and biological assessment[J]. Int J Biol Macromol, 2013, 62: 180-187.
    [9]
    Chien WW, Allas S, Rachinel N, et al. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase[J]. Invest New Drugs, 2014, 32(5): 795-805.
    [10]
    Sun XF, Liu T, Ling Y, et al. Advances in research of hyaluronic acid modified nanomicelles for targeting tumor therapy and drug release behavior[J]. J China Pharm Univ(中国药科大学学报), 2019,50(6):641-647.
    [11]
    He YJ, Tu TH, Su MK, et al. Facile construction of metallo-supramolecular poly(3-hexylthiophene)-block-poly(ethylene oxide) diblock copolymers via complementary coordination and their self-assembled nanostructures[J]. J Am Chem Soc, 2017, 139(11): 4218-4224.
    [12]
    Meng XW, Ha W, Cheng C, et al. Hollow nanospheres based on the self-assembly of alginate-graft-poly(ethylene glycol) and α-cyclodextrin[J]. Langmuir, 2011, 27(23): 14401-14407.
    [13]
    Stellmach B. Bestimmungsmethoden Enzyme(酶的测定方法)[M]. Beijing: China Light Industry Press, 1992: 85-88.
    [14]
    Zhou YL, Zhang M, He D, et al. Erratum: Uricase alkaline enzymosomes with enhanced stabilities and anti-hyperuricemia effects induced by favorable microenvironmental changes[J]. Sci Rep, 2017, 7: 46390.
    [15]
    Xiong HR, Zhou YL, Zhou QX, et al. Nanosomal microassemblies for highly efficient and safe delivery of therapeutic enzymes[J]. ACS Appl Mater Interfaces, 2015, 7(36): 20255-20263.
    • Related Articles

  • Related Articles

    [1]WANG Ziyuan, TAO Hui, XIAO Yingxue, YIN Zhiqi. Network pharmacology-based study of the mechanism of Ginkgo biloba extract (GBE) in the treatment of atherosclerosis by activating PPARγ[J]. Journal of China Pharmaceutical University, 2025, 56(2): 225-235. DOI: 10.11665/j.issn.1000-5048.2024032301
    [2]DONG Xiaoqiang, WEN Chang, XU Jindan, SHI Lexue, HU Yulong, LI Jieming, DONG Chunhong, DING Kan. Research progress on active mechanism and structure feature of polysaccharides from Zizyphus jujube in Rhamnaceae plants[J]. Journal of China Pharmaceutical University, 2024, 55(4): 443-453. DOI: 10.11665/j.issn.1000-5048.2024051301
    [3]LU Zhipeng, XU Qinglong, CHEN Panpan, QIN Yajuan, TANG Lijun, LI Tingyou. Research progress of radioprobes targeting fibroblast activating protein[J]. Journal of China Pharmaceutical University, 2022, 53(6): 651-662. DOI: 10.11665/j.issn.1000-5048.20220603
    [4]MA Rui, TIAN Jinhua, JIANG Jun, JIN Xin. Inhibitory activities of ginsenosides on the activation of NLRP3 inflammasome[J]. Journal of China Pharmaceutical University, 2016, 47(5): 614-618. DOI: 10.11665/j.issn.1000-5048.20160519
    [5]ZHU Kuiniu, WU Zhengfeng, JIANG Cuihua, CAO Lanjie, ZHANG Jian, YIN Zhiqi. Advances on hypoglycemic activity and mechanism of triterpenoids[J]. Journal of China Pharmaceutical University, 2015, 46(6): 764-770. DOI: 10.11665/j.issn.1000-5048.20150622
    [6]SHEN Kai, KOU Junping, YU Boyang. Research advances in the mechanisms of active components in Chinese materia medica against oxidative stress-induced neuronal apoptosis[J]. Journal of China Pharmaceutical University, 2015, 46(5): 532-540. DOI: 10.11665/j.issn.1000-5048.20150503
    [7]WU Keqin. Antitumor activity and mechanism of saikosaponin D combined with oxaliplatin on A549 cells-bearing nude mice[J]. Journal of China Pharmaceutical University, 2015, 46(3): 355-358. DOI: 10.11665/j.issn.1000-5048.20150316
    [8]ZHANG Qian, CHEN Cen, YANG Fengqing, XIA Zhining. Mechanism of agonist-induced platelet activation and research progress of anti-platelet drugs[J]. Journal of China Pharmaceutical University, 2014, 45(6): 632-648. DOI: 10.11665/j.issn.1000-5048.20140604
    [9]SONG Huayuan, ZHOU Danli, HAN Yuan, LIU Wentao. Baicalin attenuates morphine tolerance through suppressing spinal microglia activation in mice[J]. Journal of China Pharmaceutical University, 2014, 45(3): 346-351. DOI: 10.11665/j.issn.1000-5048.20140317
    [10]CHENG Yu-si, DAI De-zai, JI Hui, DAI Yin. Mechanism of endothelin receptor antagonist CPU0213 and calcium antagonist CPU86017 ameliorated rats′ heart failure induced by isoproterenol[J]. Journal of China Pharmaceutical University, 2011, 42(1): 58-63.

  • Cited by

    Periodical cited type(4)

    1. 谢金平，黄淼，朱梦雅，陈怡，邵蓉. 监管科学视角下增材制造(3D打印)药物研发上市关键问题及监管政策研究. 中国食品药品监管. 2025(02): 50-61 .
    2. 王美晴，段小群. 3D打印技术在药物制剂领域的研究进展. 广东化工. 2024(02): 67-68+62 .
    3. 张隽齐，杨柳榴，陈芳. 3D打印技术在膜剂制备中的研究进展. 中国医药工业杂志. 2024(03): 326-334 .
    4. 谭志柱，梁兆铭，邓永健. 3D打印技术在汽车轮胎模具领域的应用案例分析. 机电工程技术. 2024(12): 131-134 .

    Other cited types(4)

Catalog

    Get Citation
    PDF
    XML
    Article views PDF downloads Cited by(8)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：365886

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return